Welcome to our dedicated page for Celularity news (Ticker: CELU), a resource for investors and traders seeking the latest updates and insights on Celularity stock.
Celularity Inc. (NASDAQ: CELU), headquartered in Florham Park, N.J., is a trailblazer in the field of cellular medicine. As a clinical-stage biotechnology company, Celularity is at the forefront of developing off-the-shelf, placental-derived allogeneic cell therapies. Its innovative products include unmodified natural killer (NK) cells, genetically-modified NK cells, T-cells engineered with a chimeric antigen receptor (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs). These therapies target a diverse range of conditions such as cancer, infectious diseases, and degenerative disorders.
Celularity is also a pioneer in the development and manufacture of advanced biomaterials derived from the postpartum placenta. The unique biology and availability of the placenta allow Celularity to create accessible, effective, and affordable therapeutic solutions that address significant global health challenges.
Recent Achievements and Current Projects:
- The company has received IND clearance from the FDA and is set to begin a Phase 1/2 study in 2024 with its placental-derived cell therapy.
- The Healthcare Common Procedure Coding System (HCPCS) Q code approval for Biovance® 3L has been granted by the Centers for Medicare and Medicaid Services (CMS). This code enhances the use of Biovance® 3L for wound care in office settings, enabling broader adoption and growth.
- Celularity has presented promising data from in vivo studies of its PT-CD16VS, a genetically modified allogeneic cell therapy, in combination with various monoclonal antibodies. This data highlights the therapy’s potential in treating HER2-positive cancers and other conditions.
Financial Condition and Partnerships:
The company’s financial health is under scrutiny as it works to regain compliance with Nasdaq listing requirements. Celularity is actively developing a plan to submit to Nasdaq by June 17, 2024, to address its delinquent reports. Meanwhile, the company anticipates continued growth through its advanced cell therapies and biomaterials.
Celularity’s partnerships, particularly in the field of regenerative medicine, exemplify its commitment to innovation and excellence. The company’s state-of-the-art manufacturing facility further supports its ability to produce advanced cell therapies at scale, aiming to meet the unmet needs of patients worldwide.
For more detailed information and the latest updates, visit the official website www.celularity.com.
Celularity Inc. (Nasdaq: CELU) announced preliminary results from its Phase 1 trial of CYNK-001, targeting relapsed refractory acute myeloid leukemia (R/R AML) and measurable residual disease (MRD) positive AML. In a four-dose regimen of CYNK-001, two of four R/R AML patients achieved an objective response by Day 28, while one of three MRD positive patients reached MRD negativity with a three-dose regimen. The treatment was generally well-tolerated, with no dose-limiting toxicities observed. Following these results, Celularity will refine its trial design for a next-generation NK cell therapy, CYNK-301, focusing on optimizing efficacy. These findings will contribute to advancing NK-cell therapies in a challenging clinical environment.
Celularity Inc. (Nasdaq: CELU) announced that its CEO, Robert Hariri, will deliver a keynote address at the International Precision Medicine Center (IPMC) Conference in Goyang City, South Korea, on April 11-12, 2023. The conference theme, "Beyond Longevity: Live 120 Like 50," will explore advancements in cell and gene therapy that enhance longevity. Dr. Hariri emphasized the need for well-controlled studies to examine the potential benefits of cell therapy in extending lifespan and improving quality of life. The event will also focus on building a global longevity science hub, advancing the field of precision medicine centered on cell therapy.
Celularity Inc. (Nasdaq: CELU) has announced a registered direct offering of approximately 9.23 million shares of its Class A common stock, alongside warrants to purchase an equivalent number of shares, at a combined price of $0.65 per share. The offering is expected to generate around $6 million in gross proceeds before expenses. The exercise price of the warrants is set at $0.75, with a six-month post-issuance exercise window and a five-year expiration. Existing warrants will also be amended to lower their exercise price to $0.75. The transaction is scheduled to close around April 10, 2023, pending customary conditions.
Celularity Inc. (Nasdaq: CELU) announced an upcoming oral and poster presentation at the 2023 Annual Meeting Society for Biomaterials in San Diego from April 19-22, 2023. The presentation will focus on the role of decellularized dehydrated human amniotic membranes in supporting human tenocytes in vitro. This research is part of Celularity's commitment to developing placental-derived cell therapies and biomaterials. CEO Robert Hariri emphasized the potential therapeutic benefits of their unique technology platform, which utilizes postpartum placenta-derived products for regenerative medicine.
FAQ
What is the current stock price of Celularity (CELU)?
What is the market cap of Celularity (CELU)?
What does Celularity Inc. specialize in?
What recent achievements has Celularity accomplished?
What are some of the key products developed by Celularity?
Where is Celularity Inc. headquartered?
What are the target indications for Celularity’s therapies?
What makes Celularity’s approach unique?
What financial challenges is Celularity currently facing?
How does Celularity plan to scale its manufacturing?
How can investors get in touch with Celularity?
Where can I find more information about Celularity?
